How EMPAVELI can help | HEMOGLOBIN
Increased hemoglobin with EMPAVELI
Superior improvements in hemoglobin (Hb) in people who had previously received a C5i: results at Week 16 Primary goal in the PEGASUS study: to explore whether EMPAVELI was better at improving Hb levels than a C5i (eculizumab) in people living with paroxysmal nocturnal hemoglobinuria (PNH)
Peg is an adult with PNH who's taken EMPAVELI.
In people who had previously received a C5i (PEGASUS)
Hb improvement was maintained through the 48-week study
People taking EMPAVELI had a 2.37 g/dL Hb INCREASE
SUPERIOR Hb DIFFERENCE of 3.84 g/dL with EMPAVELI compared to eculizumab ( P <0.0001)
Average change in Hb levels from beginning to Week 48
People taking eculizumab had a 1.47 g/dL Hb DECREASE
View graph of Hb improvement over 16 weeks
IMPORTANT SAFETY INFORMATION (cont’d) Who should NOT take EMPAVELI? Do not take EMPAVELI if you: are allergic to pegcetacoplan or any of the ingredients in EMPAVELI.
C5i=C5 inhibitor; EMP=EMPAVELI; OLP=open-label period; RCP=randomized control period; SE=standard error.
have a serious infection caused by encapsulated bacteria, including Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae type B when you are starting EMPAVELI treatment.
Please see full Important Safety Information, including Boxed WARNING regarding risk of serious infections, on pages 38-39, and the full Prescribing Information and Medication Guide.
10
11
Made with FlippingBook - professional solution for displaying marketing and sales documents online